- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Akụkọ
-
Akụkọ
Ihe mgbaàmà nke ọrịa kansa imeju 2026: Ihe ịrịba ama kacha ọhụrụ & Ọnụ Ọgwụgwọ - Ụlọ ọgwụ dị nso m
Ọdịnaya Ịghọta ihe ịrịba ama kachasị ọhụrụ nke ọrịa cancer imeju na 2026 ihe ize ndụ yana onye kwesịrị nyocha usoro nchọpụta nchọpụta maka ịkwado nhọrọ ọgwụgwọ ọrịa imeju dị na 2026 Imeju C...
Ọgwụgwọ ọrịa kansa akpa ume nke mbụ 2026: Ntuziaka ọhụrụ & Ọgwụgwọ Kacha ọhụrụ
Ọdịnaya Ịghọta Ọrịa cancer akpa ume nke mbụ na ụkpụrụ nchọpụta 2026 emelitere ntuziaka ọgwụgwọ maka ọganihu ọrịa kansa akpa ume na-abụghị nke obere cell na obere ọgwụgwọ ọrịa cancer akpa ume na-apụta ...
Ọgwụ Ọgwụgwọ Ọrịa Cancer akpa ume 2026: Ọgwụ ọhụrụ KRAS & HER2
Ọdịnaya Oge Ọhụrụ nke ọgwụ ziri ezi na ọrịa cancer akpa ume na mmepe ọgwụgwọ HER2 ezubere na Ọganihu na ọgwụgwọ KRAS Inhibitor Evolushọn nke ọgwụgwọ EGFR ezubere iche ntụle nke isi L...
Ịwa Ọgwụgwọ Ọrịa Cancer akpa ume 2026: Ọhụrụ Neo-Adjuvant Breakthroughs
Ọdịnaya Evolution nke ịwa ahụ ọgwụgwọ ọrịa kansa akpa ume na 2026 Mmeri na Immunotherapy dabere na Neo-Adjuvant Regimens Therapy Ezubere maka usoro ịwa ahụ nke ndị ọrịa na-anya ọkwọ ụgbọ ala…
Ngwọta Ọrịa cancer akpa ume dị ukwuu nke obere cell 2026: Ọhụụ Iza-bren & Tarlatamab ọhụrụ
Ọdịnaya Ọdịnaya Mgbanwe nke Nnukwu Ọgwọ Ọrịa Ọrịa Cancer Na-ahụ Maka Ụkwụ Obere Cell Iza-bren: Mgbanwe Paradigm na Bispecific ADC Therapy Tarlatamab na ịrị elu nke T-Cell na-etinye nchekwa na nnabata na...
Nhọrọ ọgwụgwọ ọrịa cancer akpa ume obere cell 2026: ADC ọhụrụ & Immunotherapy Breakthroughs
Ọdịnaya Ịghọta Ọnọdụ Ọdịnihu dị ugbu a nke Nhọrọ Ọgwụgwọ Ọrịa Cancer Obere Cell nke Mbụ: Ngwakọta Immunotherapy The Rise of Antibody-Drug Conjugates (ADCs) Ezubere iche DLL3:...
